Scinai Immunotherapeutics (SCNI) Long-Term Investments (2016 - 2022)

Scinai Immunotherapeutics has disclosed Long-Term Investments across 7 years of filings, most recently posting $30.1 million for Q1 2022.

• Long-Term Investments for Q1 2022 came in at $30.1 million, down 99.97% year-over-year; the trailing twelve-month figure through Mar 2022 was $30.1 million (down 99.97% YoY), and the FY2020 annual result was -$53.5 million, down 214.19% from the prior year.
• Long-Term Investments came in at $30.1 million for Q1 2022 at Scinai Immunotherapeutics, up from $25.1 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $144.4 billion in Q1 2020 to a low of -$70.0 million in Q3 2020.
• The 5-year median for Long-Term Investments is $30.4 million (2018), against an average of $29.3 billion.
• Across the five-year window, Long-Term Investments plunged 317.66% in 2019 and surged 6930824.92% in 2020, its largest moves.
• Scinai Immunotherapeutics' Long-Term Investments stood at $30.8 million in 2018, then jumped by 52.29% to $46.8 million in 2019, then tumbled by 214.19% to -$53.5 million in 2020, then soared by 146.92% to $25.1 million in 2021, then gained by 19.88% to $30.1 million in 2022.
• The last three Long-Term Investments figures came in at $30.1 million (Q1 2022), $25.1 million (Q3 2021), and $88.0 billion (Q2 2021), per Business Quant data.